文献速递白血病MDS 与骨髓增殖性肿瘤

便携式医疗指令与急性髓系白血病及骨髓增生异常综合征的临终措施

Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2021-01-01

本研究回顾性分析358例在5年内死亡的成人AML或MDS患者,探讨MOLST表完成时机与临终关怀的关系。约三分之一患者在死亡前30天以上完成至少一份MOLST表,这些患者接受输血、化疗、生命维持治疗及ICU入住的风险显著降低,而使用临终关怀服务的可能性更高。较早完成MOLST表与MDS或AML患者临终期低强度医疗相关。

要点

  • 约三分之一AML或MDS患者在死亡前30天以上完成MOLST表。
  • 较早完成MOLST表者输血、化疗、生命维持治疗及ICU入住风险显著降低。
  • 较早完成MOLST表者使用临终关怀服务的可能性更高。

核心结论

  • 在AML或MDS患者中,较早完成MOLST表与临终期低强度医疗相关。

研究设计与样本

  • 回顾性研究,纳入单中心及其附属机构5年内死亡的358例成人AML或MDS患者。

主要发现

  • 约三分之一患者在死亡前30天以上完成至少一份MOLST表。
  • 与死亡前30天内完成或从未完成者相比,死亡前30天以上完成MOLST表者接受输血的风险更低(AOR 0.39;P < .01)。
  • 死亡前30天以上完成MOLST表者接受化疗的风险更低(AOR 0.24;P < .01)。
  • 死亡前30天以上完成MOLST表者接受生命维持治疗的风险更低(AOR 0.21;P < .01),入住ICU的风险也更低(AOR 0.21;P < .01)。
  • 死亡前30天以上完成MOLST表者使用临终关怀服务的可能性更高(AOR 2.72;P < .01)。

临床怎么用

  • 对AML或MDS患者,可考虑早期开展目标导向讨论并完成便携式医疗指令,以降低临终期高强度医疗。

局限性

  • 研究为单中心回顾性设计,结果可能受机构实践和患者选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acute myeloid leukemia (AML) or a myelodysplastic syndrome (MDS) experience high rates of hospitalization, intensive care unit (ICU) admission, and in-hospital death at the end of life. Early goals-of-care (GOC) discussions may reduce the intensity of end-of-life (EOL) care. Portable Medical Order forms, known as Medical Orders for Life-Sustaining Treatment (MOLST) forms in New York state, assist patients in translating GOC discussions into specific medical orders that communicate their wishes during a medical emergency. To determine whether the timing of completion of a MOLST form is associated with EOL care in patients with AML or MDS, we conducted a retrospective study of 358 adult patients with AML or MDS treated at a single academic center and its affiliated sites, who died during a 5-year period. One-third of patients completed at least 1 MOLST form >30 days before death. Compared with patients who completed a MOLST form within 30 days of death or never, those who completed a MOLST form >30 days before death were less likely to receive transfusion (adjusted odds ratio [AOR], 0.39; P < .01), chemotherapy (AOR, 0.24; P < .01), or life-sustaining treatments (AOR, 0.21; P < .01) or to be admitted to the ICU (AOR, 0.21; P < .01) at EOL. They were also more likely to use hospice services (AOR, 2.72; P < .01). Earlier MOLST form completion was associated with lower intensity of care near EOL in patients with MDS or AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. LoCastro M, Baran AM, Liesveld JL, et al. Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes. Blood Adv. 2021. PMID: 34525170. doi:10.1182/bloodadvances.2021004775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。